ABSTRACT
ABSTRACT BACKGROUND: Liver transplantation (LTx) is the primary and definitive treatment of acute or chronic cases of advanced or end-stage liver disease. Few studies have assessed the actual cost of LTx categorized by hospital unit. OBJECTIVE: To evaluate the cost of LTx categorized by unit specialty within a referral center in southern Brazil. METHODS: We retrospectively reviewed the medical records of 109 patients undergoing LTx between April 2013 and December 2014. Data were collected on demographic characteristics, etiology of liver disease, and severity of liver disease according to the Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores at the time of LTx. The hospital bill was transformed into cost using the full absorption costing method, and the costs were grouped into five categories: Immediate Pretransplant Kit; Specialized Units; Surgical Unit; Intensive Care Unit; and Inpatient Unit. RESULTS: The mean total LTx cost was US$ 17,367. Surgical Unit, Specialized Units, and Intensive Care Unit accounted for 31.9%, 26.4% and 25.3% of the costs, respectively. Multivariate analysis showed that total LTx cost was significantly associated with CTP class C (P=0.001) and occurrence of complications (P=0.002). The following complications contributed to significantly increase the total LTx cost: septic shock (P=0.006), massive blood transfusion (P=0.007), and acute renal failure associated with renal replacement therapy (dialysis) (P=0.005). CONCLUSION: Our results demonstrated that the total cost of LTx is closely related to liver disease severity scores and the development of complications.
RESUMO CONTEXTO: O transplante hepático (TxH) é o principal e definitivo tratamento de casos agudos ou crônicos de doenças hepáticas avançadas ou terminais. Poucos estudos têm avaliado o custo real do TxH categorizado por setores hospitalares. OBJETIVO: Avaliar o custo do TxH categorizado por especialidade da unidade em um centro de referência na região sul do Brasil. MÉTODOS: Analisamos retrospectivamente os prontuários de 109 pacientes submetidos a TxH entre abril de 2013 e dezembro de 2014. Foram coletados dados sobre características demográficas, etiologia da doença hepática e gravidade da doença hepática de acordo com os escores Child-Turcotte-Pugh (CTP) e Model for End-stage Liver Disease (MELD) no momento do TxH. A conta hospitalar foi transformada em custo pelo método de custeio por absorção integral, e os custos foram agrupados em cinco categorias: Kit Pré-Transplante Imediato; Unidades Especializadas; Centro Cirúrgico; Unidade de Terapia Intensiva; e Unidade de Internação. RESULTADOS: O custo médio total do TxH foi de US$ 17.367. O Centro Cirúrgico, as Unidades Especializadas e a Unidade de Terapia Intensiva responderam por 31,9%, 26,4% e 25,3% dos custos, respectivamente. A análise multivariada demonstrou que o custo total do TxH se associou significativamente ao escore CTP classe C (P=0,001) e ao desenvolvimento de intercorrências (P=0,002). As seguintes intercorrências contribuíram para aumentar significativamente o custo do TxH: choque séptico (P=0,006), politransfusão sanguínea (P=0,007) e insuficiência renal aguda associada à terapia renal substitutiva (diálise) (P=0,005). CONCLUSÃO: Nossos resultados demonstraram que o custo total do TxH guarda uma estreita relação com os escores de gravidade da doença hepática e com o desenvolvimento de intercorrências.
Subject(s)
Humans , Male , Female , Adult , Aged , Liver Transplantation/economics , Liver Diseases/surgery , Brazil , Retrospective Studies , Liver Transplantation/adverse effects , Hospital Costs , Length of Stay , Liver Diseases/economics , Middle AgedABSTRACT
RESUMEN Objetivos. Estimar el gasto de bolsillo en salud (GBS) e identificar sus factores asociados en adultos mayores peruanos. Materiales y métodos. Estudio transversal analítico de la Encuesta Nacional de Hogares sobre Condiciones de Vida y Pobreza (ENAHO) 2017. Se consideró como adulto mayor a todo individuo de 60 y más años y el GBS como variable principal de estudio. Se estimaron razones de prevalencia (RP) y razones de prevalencia ajustada (RPa) para cada uno de los factores asociados a GBS. Las medias del GBS fueron estimadas mediante un modelo lineal generalizado con distribución gamma y función de enlace log. Todos los intervalos de confianza (95 %) de los estimadores fueron calculados mediante bootstrapping con el método basado en la normal. Resultados. Se incluyeron 18 386 adultos mayores, de los cuales en el 56,5 % se reportó GBS. La media y mediana del GBS es de 140,8 (USD 43,2) y 34,5 (USD 10,6) soles, respectivamente. Factores como procedencia urbana, mayor nivel de educación, padecer enfermedades crónicas y mayores gastos per cápita aumentan hasta 1,6 veces la probabilidad de GBS. En los afiliados al Seguro Integral de Salud (SIS) se reduce el GBS en 63,0 soles (USD 19,3) comparado con aquellos sin ningún seguro de salud. Conclusiones. Seis de cada diez adultos mayores peruanos reportó GBS para atender su salud. Esto genera inequidad en el acceso a los servicios de salud, principalmente para los grupos socialmente vulnerables. Se sugiere investigar el impacto económico de los seguros sanitarios y el abordaje preventivo-promocional de las enfermedades crónicas, en aras de reducir el GBS y mejorar la eficiencia del sistema de salud peruano.
ABSTRACT Objectives . To estimate out-of-pocket spending on health (GBS) and identify its associated factors in Peruvian older adults. Materials and Methods. Analytical cross-sectional study of the National Household Survey on Living Conditions and Poverty (ENAHO) 2017. Older adults were considered to be all individuals aged 60 and over and the GBS was considered the main study variable. Prevalence ratios (PR) and adjusted prevalence ratios (PRa) were estimated for each of the factors associated with GBS. GBS means were estimated using a generalized linear model with gamma distribution and log binding function. All confidence intervals (95%) of the estimators were calculated by bootstrapping with the normal-based method. Results . Eighteen 386 older adults were included, of which 56.5% reported GBS. The mean and median GBS is S/. 140.8 (USD 43.2) and S/. 34.5 (USD 10.6), respectively. Factors such as urban origin, a higher level of education, chronic diseases and higher per capita expenses increase the probability of GBS by up to 1.6 times. In those affiliated to the Integral Health Insurance (SIS), the GBS is reduced by 63.0 soles (USD 19.3) compared to those without any health insurance. Conclusions . Six out of ten older Peruvian adults reported GBS to attend to their health needs. This generates an access inequity in terms of health services, mainly for socially-vulnerable groups. We suggest researching into the economic impact of health insurance and the preventive-promotional approach to chronic diseases, in order to reduce GBS and improve the efficiency of the Peruvian health system.
Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Poverty/statistics & numerical data , Social Conditions/statistics & numerical data , Health Expenditures/statistics & numerical data , Peru , Cross-Sectional Studies , Health SurveysABSTRACT
Objective: To explore the changes of incidence of major vascular lesions after intensive intervention of multiple controllable risk factors in the type 2 diabetes mellitus (T2DM) patients in Han population in Northeast China, and to establish an effective, standardized and cost-effective intervention scheme for the primary prevention of major vascular lesions of the T2DM patients. Methods: A total of 300 T2DM patients newly diagnosed or diagnosed in one year without major vascular lesions were randomly divided into conventional treatment group (n= 150) and intensive intervention group (n=150). The clinical study method of parallel control was used to intervene in the some controllable risk factors for 2 years to varying degrees. The body mass index (BMD, waist/hip ratio (WHR), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FPG), 2 h postprandial blood glucose (2 h PBG), glycosylated hemoglobin (HbAlc), serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-c), high density lipoprotein (HDL-c), intima media thickness (IMT) and incidence of majoy vascular lesions of atherosclerosis (AS) of the patients in two groups were measured, and the medical expenses of the patients were analyzed statistically. Results: After 2-year-follow-up, the DBP, FBG, 2 h PBG, HbAlc, TG, TC and HDL-c of the patients in conventional treatment group were significantly lower than those before treatment (P
ABSTRACT
BACKGROUND@#Ischemic heart disease (IHD/ICD10: I20-I25) is the second leading cause of deaths in Japan and accounts for 40% of deaths due to heart diseases. This study aimed to calculate the economic burden of IHD using the cost of illness (COI) method and to identify key factors that drive the change of the economic burden of IHD.@*METHODS@#We calculated the cost of illness (COI) every 3 years from 1996 to 2014 using governmental statistics. We then predicted the COI for every 3 years starting from 2017 up to 2029 using the fixed and variable model estimations. Only the estimated future population was used as a variable in the fixed model estimation. By contrast, variable model estimation considered the time trend of health-related indicators over the past 18 years. We derived the COI from the sum of direct and indirect costs (morbidity and mortality).@*RESULTS@#The past estimation of COI slightly increased from 1493.8 billion yen in 1996 to 1708.3 billion yen in 2014. Future forecasts indicated that it would decrease from 1619.0 billion yen in 2017 to 1220.5 billion yen in 2029.@*CONCLUSION@#The past estimation showed that the COI of IHD increased; in the mixed model, the COI was predicted to decrease with the continuing trend of health-related indicators. The COI of IHD in the future projection showed that, although the average age of death increased by social aging, the influence of the number of deaths and mortality cost decreased.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Cost of Illness , Forecasting , Japan , Models, Theoretical , Myocardial Ischemia , EconomicsABSTRACT
<b>Objective: </b>To examine the usefulness of inquiries made by hospital pharmacists.<br><b>Methods: </b>This study was conducted a survey about the actual condition of inquiries at 5 hospitals.<br><b>Results: </b>The prescriptions subjected to inquiry accounted for 1.5% of the inpatient prescriptions and 0.3% of the injection prescriptions. In cases of “Incomplete entry in the prescription” for the subcategory of “Question about safety,” drug costs without the impact of pharmaceutical inquiries were calculated on the assumption that the concerned drugs should have been generally prescribed. Our results showed that the total savings in medical costs were 30,673 yen for the inpatient prescriptions and 159,212 yen for injection prescriptions, which suggested that pharmaceutical inquiries are effective for saving medical costs for either type of prescriptions. In the case of patients in whom adverse drug reactions (ADRs) might have occurred without prescription changes, medical cost savings realized by preventing ADRs were estimated using the Diagnosis Procedure Combination/Per-Diem Payment System (DPC/PDPS). Our results showed that the savings were 1,428,710 yen for inpatient prescriptions (6 patients), which indicated that a large amount of medical costs was saved.<br><b>Conclusions: </b>Our results suggested that similar to pharmaceutical inquiries made by community pharmacists, those made by hospital pharmacists not only result in the proper delivery of drug therapy but also are useful in terms of medical economics.
ABSTRACT
Los gastos en salud y el uso de medicamentos han aumentado de forma importante en los últimos años, lo que alerta a gobiernos y entes sanitarios y puede relacionarse con algunos fenómenos: prescripción médica poco estandarizada, ganancias exageradas de la industria farmacéutica, avances en biotecnología y desperdicio de recursos, falta de comunicación entre gestores públicos y médicos clínicos y ausencia de regulación en precios de fármacos. La importancia de la farmacoeconomía se fundamenta en varios aspectos: optimización de prescripción médica, papel crucial en la comercialización y la distribución de medicamentos, capacidad de mostrar un amplio panorama del impacto social y económico de las enfermedades, como de abrir perspectivas de investigación en varios campos del conocimiento. Dentro de los tipos de estudios farmacoeconómicos se encuentran los que expresan la unidad de ingreso (costos) en términos monetarios y los resultados en unidades monetarias, naturales o de utilidad: reducción de costos (costo minimización), costo beneficio, costo utilidad y costo efectividad, como también los que estudian el panorama global de las enfermedades (análisis costo de la enfermedad). Los costos en salud se distribuyen de la siguiente manera: costos directos (médicos y no médicos), indirectos (impacto en la sociedad como unidad productiva) e intangibles (relacionados con calidad de vida de pacientes y familiares). La farmacoeconomía permite una mejor práctica clínica, sistemas de salud más eficientes y un consumo de recursos más racional. El uso de estos estudios es necesario para estructurar programas de salud y tomar decisiones. Así mismo es recomendada la inclusión de conceptos de economía de la salud en programas de medicina y ciencias de la salud.
Health expenditures and medication usage have increased dramatically in last years, situation that alerts governments and health authorities, and than can be related with some facts: not standardized medical prescription, excessive gains of the pharmaceutical industry, recent advances in biotechnology related with resource wastefulness, lack of communication between public health entities and clinical physicians and lack of consistent regulatory policies about drug prices. The importance of pharmacoeconomics is based on some aspects: better medical prescription, important role in commercialization and distribution of medicines, capacity of showing a broad and complete scenario of the social and economic impact of diseases, as opening research perspectives in different scientific fields. Within pharmacoeconomical analyses we can found those that show incomes (costs) in monetary units and show outcomes in monetary, natural or utility units: cost minimization, cost benefit, cost utility and cost effectiveness, and also we can found those analyses that study the general panorama of diseases (cost of illness studies). Health costs can be divided into: direct costs (medical and not medical), indirect (economical impact on society) and intangible (related with quality of life of patients and their families). Pharmacoeconomics can lead to a better medical practice, to more efficient health systems and to a more rational usage of resources. These studies are necessary for a proper structure of health programs, as for decision making. The inclusion of health economics concepts within medical and health sciences curricula is also recommended.
Subject(s)
Humans , Health Expenditures , Economics, Pharmaceutical , Drug Utilization , Quality of Life , Prescription DrugsABSTRACT
We investigated prescriptions and drug costs at admission and discharge for 35 patients hospitalized in Department of Japanese Oriental (Kampo) Medicine, Chiba University Hospital from September 2006 to October 2008. They recovered after Kampo therapy from various non-acute diseases. The number of western drugs decreased from 3.7 at admission to 2.7 at discharge, thus their drug costs per day significantly decreased from302.1yen to 227.6 yen. The cost of Kampo medicines themselves, on the other hand, did not decrease significantly. Total drug costs, however, were significantly reduced from 437.8 yen at admission to 348.0 yen at discharge, so patients' overall costs were reduced by 20%. These results indicated that the proper use of Kampo medicine for various diseases would reduce drug costs and the impact of treatment expenses on medical economics, with improvement in disease outcomes.
ABSTRACT
Health services have increasingly proven to be an innovative sector, gaining prominence in the medical industrial complex through expansion to public and international markets. International trade can foster economic development and redirect the resources and infrastructure available for healthcare in different countries in favorable or unfavorable directions. Wherever private providers play a significant role in government-funded healthcare, GATS commitments may restrict health policy options in subscribing countries. Systematic information on the impacts of electronic health services, medical tourism, health workers' migration, and foreign direct investment is needed on a case-by-case basis to build evidence for informed decision-making, so as to maximize opportunities and minimize risks of GATS commitments.
Os serviços de saúde evidenciam um padrão de inovação - na forma de expansão para mercados públicos e do comércio internacional - que os credencia a assumir um papel preponderante no complexo industrial da saúde. O comércio internacional e suas bases regulatórias, definidas no General Agreement on Trade in Services (GATS), têm o potencial de gerar desenvolvimento econômico, mas também de reordenar os recursos disponíveis para a saúde em âmbito nacional e global, em direções favoráveis ou não. Onde houver uma combinação de prestadores públicos e privados atuando na saúde pública, como no caso brasileiro, os termos do GATS admitem a interpretação de que a prestação pública recai no âmbito do GATS, criando-se restrições às opções políticas dos países para a saúde. São necessárias informações sistematizadas e específicas para cada país sobre serviços eletrônicos, movimento de pacientes e profissionais, e investimento direto estrangeiro em serviços de saúde para compor evidências que permitam decisões mais informadas sobre adesão ao GATS.
Subject(s)
Commerce , Health Services , International Cooperation , Marketing of Health Services , National Health Systems , Technological DevelopmentABSTRACT
BACKGROUND: Out-of-pocket health expenditures defined as the charges for services not covered by health insurance have received only sporadic attention. The purpose of this study was to determine the impact of sociodemographic and health characteristics on out-of-pocket health expenditures. METHODS: We used data from the 2001 National Public Health and Nutrition Survey, a nationally representative survey of community-dwelling individuals. The final sample size for this analysis was 61 individuals with age 20 and older cancer patients in Korea. Using a multiple linear regression model to control for differences in sociodemographics, self-reported health status, hospital length of stay, time since perception, and insurance status, the out-of-pocket health expenditures were estimated. RESULTS: Mean monthly out-of-pocket health expenditures were 399,300 won. The highest mean out-of-pocket health expenditures were paid by those with lung cancer, 820,000 won. In the regression analysis, insurance status, resident area, hospital length of stay, and time since perception were statistically significant determinants. Thus, those with higher hospital days, National Health Insurance, metropolitan, and more than 1 year of time since perception experienced higher economic burden. CONCLUSIONS: Policymakers should consider out-of-pocket health expenditure difference by diverse characteristics.